Postmortem Human Brain Collection (Supplement to MH67996)

描述（由申请人提供）：应NIMH（神经科学和基础行为科学部，Douglas Meinecke博士）的要求，本补充申请对应于“重度抑郁症海马萎缩”（RO1 MH 67996; PI: C. Stockmeier）的资助年度03和04。继续和扩大组织收集的补充支持请求是作为RO1 63187（06/01/02 -11/30/05）的一部分授予Gregory Ordway博士的补充死后脑收集资金（NOT-MH-01- 010）的延伸，以及在此之前NIMH为PI提供的11年的收集资金。神经影像学和死后脑研究为重度抑郁症（MDD）的海马病理提供了证据。据推测，由于神经生长和突触连接标志物的减少，海马神经pil减少，导致神经元和胶质细胞密度增加，这是MDD海马组织病理学的微观基础。为了满足父母RO1 （MH 67996）的具体目的，要求补充资金用于收集1)尸检时的人类脑组织和2)来自近亲的足够临床信息和医疗记录，以便对DSM-IV精神障碍进行回顾性评估。在知情书面同意的情况下，从生命最后两周患有重度抑郁发作的受试者和与年龄、性别、死后间隔和组织ph相匹配的精神正常对照受试者中提取脑组织。这些抑郁受试者在死亡时不接受抗抑郁或抗精神病药物治疗，所有受试者必须在神经和神经病理学上正常。重度抑郁症患者目前必须没有酒精或精神活性物质使用障碍的共病I轴诊断。存在或不存在重度抑郁症是通过共识诊断来确定的，该诊断基于医疗记录和通过DSM IV精神疾病（SCID）结构化临床访谈从所有受试者的近亲收集的数据。按照目前的收集速度，今后两年每年收集6-8名重度抑郁症患者和大约10名正常对照患者将能够实现资助的具体目标。目前NIH对c博士的资助。Stockmeier， G. Ordway， G. Rajkowska， R. Duman， B. Karolewicz和M. Austin仅仅依靠这本脑组织补编来更好地理解主要精神疾病的细胞和分子病理生理学。

DESCRIPTION (provided by applicant): At the request of NIMH (Division of Neuroscience and Basic Behavioral Science, Dr. Douglas Meinecke), this Supplemental application corresponds to Funded Years 03 and 04 of "Hippocampal Atrophy in Major Depression (RO1 MH 67996; PI: C. Stockmeier). The request for Supplemental support to continue and expand tissue collection is an extension of Supplemental Postmortem Brain Collection funding (NOT-MH-01- 010) awarded to Dr. Gregory Ordway as part of RO1 63187 (06/01/02 -11/30/05), and 11 years of NIMH funding for collection to the PI prior to that. Neuroimaging and postmortem brain studies provide evidence for hippocampal pathology in major depressive disorder (MDD). It is hypothesized that a decrease in hippocampal neuropil, in response to diminished markers of neural growth and synaptic connection, resulting in an increase in neuronal and glial density, is the microscopic basis for the histopathology of the hippocampus in MDD. To meet the Specific Aims of the parent RO1 (MH 67996), supplemental funds are requested for the collection of 1) human brain tissue at autopsy and 2) sufficient clinical information from next-of-kin and medical records for retrospective assessment of DSM-IV psychiatric disorders. With informed written consent, brain tissue is sought from subjects suffering a major depressive episode in the last two weeks of life and psychiatrically-normal control subjects matched for age, gender, postmortem interval arid tissue pH. These depressed subjects will not be receiving antidepressant or antipsychotic treatment at the time of death and all subjects must be neurologically and neuropathologically normal. Subjects with MDD must have no current co-morbid Axis I diagnosis of an alcohol or psychoactive substance use disorder. The presence or absence of MDD is determined by consensus diagnosis based on medical records and data gathered from next-of-kin of all subjects with the Structured Clinical Interview for DSM IV Psychiatric Disorders (SCID). At current collection rates, the collection of 6-8 subjects with MDD and about 10 normal control subjects per year for the next two years will permit achievement of the funded specific aims. Current NIH funding to Drs.C. Stockmeier, G. Ordway, G. Rajkowska, R. Duman, B. Karolewicz and M. Austin depends solely on this Supplement for brain tissue to better understanding of the cellular and molecular pathophysiology of the major mental illnesses.